{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T04:07:01Z","timestamp":1775621221059,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:00:00Z","timestamp":1793923200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["D43 TW011532"],"award-info":[{"award-number":["D43 TW011532"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028182","name":"AIDS Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.08.015","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T17:55:48Z","timestamp":1758822948000},"page":"1003-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacists\u2019 Knowledge and Perceptions of Buprenorphine at New York State Pharmacies: Identifying the Extent of Pharmacy-Level Barriers to Access Buprenorphine"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8434-1811","authenticated-orcid":false,"given":"Mariana","family":"Buziashvili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Col\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Boos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piper","family":"Coalson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Stancliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yin John","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.08.015_bib0001","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). https:\/\/www.samhsa.gov\/substance-use\/treatment\/options\/buprenorphine. Accessed October 10, 2023."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2025.08.015_bib0002","first-page":"1","article-title":"The ASAM National Practice Guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J Addict Med"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0003","unstructured":"US Department of Justice, Drug Enforcement Administration. Buprenorphine. https:\/\/www.deadiversion.usdoj.gov\/drug_chem_info\/buprenorphine.pdf#search=buprenorphine. Accessed September 14, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0004","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA: statuses, regulations, and guidance. https:\/\/www.samhsa.gov\/substance-use\/treatment\/statutes-regulations-guidelines Accessed October 10, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0005","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). SAMHSA: buprenorphine dispensing by opioid treatment programs (OTPs). https:\/\/www.samhsa.gov\/substance-use\/treatment\/opioid-treatment-program\/become-otp\/buprenorphine-dispensing. Accessed September 13, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0006","unstructured":"Varghese R, Johnson K, Feng B, et al; IMPAQ International. Final Research Report: buprenorphine prescribing by nurse practitioners, physician assistants, and physicians after CARA 2016. https:\/\/www.macpac.gov\/wp-content\/uploads\/2019\/11\/Buprenorphine-Prescribing-by-Nurse-Practitioners-Physician-Assistants-and-Physicians-after-CARA-2016.pdf. Accessed October 16, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108083","article-title":"Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: a cross-sectional study","volume":"213","author":"Roehler","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMp1813961","article-title":"The SUPPORT for Patients and Communities Act\u2014what will it mean for the opioid-overdose crisis?","volume":"380","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0009","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJMp2002908","article-title":"When prescribing isn\u2019t enough \u2014 pharmacy-level barriers to buprenorphine access","volume":"383","author":"Cooper","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0010","unstructured":"Office of the Secretary, Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder. Accessed April 16, 2024."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0011","unstructured":"Consolidated Appropriations Act. One Hundred Seventeenth Congress of the United States of America. https:\/\/www.congress.gov\/117\/bills\/hr2617\/BILLS-117hr2617enr.pdf, 2023. Accessed December 4, 2024."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0012","unstructured":"SAMHSA: Waiver Elimination (MAT Act). https:\/\/www.samhsa.gov\/substance-use\/treatment\/statutes-regulations-guidelines\/mat-act. Accessed April 11, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0013","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10826084.2019.1670210","article-title":"Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study","volume":"55","author":"Ventricelli","year":"2020","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0017","unstructured":"American Society of Addiction Medicine. Reducing Barriers to Lifesaving Treatment: Report on the Findings from ASAM\u2019s Pharmacy Access Survey. https:\/\/sitefinitystorage.blob.core.windows.net\/sitefinity-production-blobs\/docs\/default-source\/advocacy\/reports\/asam-pharmacy-access-survey-report-final-11.7.22.pdf?sfvrsn=6da97680_3. Accessed March 24, 2024."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0019","unstructured":"U.S. Department of Justice, Drug Enforcement Administration, Suspicious Orders Report System (SORS). https:\/\/www.deadiversion.usdoj.gov\/sors\/sors.html. Accessed November 20, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0020","doi-asserted-by":"crossref","DOI":"10.2196\/32133","article-title":"Where opioid overdose patients live far from treatment: geospatial analysis of underserved populations in New York State","volume":"8","author":"Abell-Hart","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0021","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1080\/10826084.2019.1653324","article-title":"Patient barriers and facilitators to medications for opioid use disorder in primary care","volume":"54","author":"Tofighi","year":"2019","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0022","unstructured":"Office of Budget Policy and Analysis. Continuing crisis: drug overdose deaths in New York. https:\/\/www.osc.state.ny.us\/reports\/continuing-crisis-drug-overdose-deaths-new-york#endnote-012. Accessed November 15, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0023","unstructured":"New York State Department of Health (NYSDOH). AIDS Institute: drug user health. https:\/\/www.health.ny.gov\/diseases\/aids\/general\/about\/drug_user_health.htm#bupe. Accessed December 21, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0025","unstructured":"New York State Department of Health (NYSDOH). Opioid poisoning, overdose and prevention. 2015 report to the Governor and NYS Legislature. https:\/\/www.health.ny.gov\/diseases\/aids\/general\/opioid_overdose_prevention\/docs\/annual_report2015.pdf. Accessed September 10, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0026","unstructured":"State Public Health Law. Section 3306: Schedules of controlled substances. https:\/\/www.nysenate.gov\/legislation\/laws\/PBH\/3306. Accessed October 10, 2023."},{"key":"10.1016\/j.clinthera.2025.08.015_bib0027","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dar.12032","article-title":"Factors influencing pharmacy services in opioid substitution treatment","volume":"32","author":"Chaar","year":"2013","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugpo.2015.11.006","article-title":"Community pharmacy services for people with drug problems over two decades in Scotland: implications for future development","volume":"27","author":"Matheson","year":"2016","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.clinthera.2025.08.015_bib0029","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.drugpo.2014.05.009","article-title":"Community pharmacy services for drug misuse: attitudes and practices of Finnish pharmacists","volume":"25","author":"Uosukainen","year":"2014","journal-title":"Int J Drug Policy"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:56:11Z","timestamp":1774947371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825002978"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacists\u2019 Knowledge and Perceptions of Buprenorphine at New York State Pharmacies: Identifying the Extent of Pharmacy-Level Barriers to Access Buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}